Lupin acquires nine brands of Medical Nutritional Institute in South Africa

MNI is dedicated to developing and offering phytochemical (plant-based) products and healthcare solutions, aimed at treating metabolic syndrome

Calquence granted priority review in US for patients with untreated mantle cell lymphoma

Based on ECHO Phase III trial which demonstrated Calquence combination reduced risk of disease progression or death by 27% compared to standard-of-care chemoimmunotherapy

Suven Life Sciences to present positive results from Phase-2a Proof-of-Concept Study of Ropanicant

The company plans to advance Ropanicant into double-blind, placebo-controlled Phase-2b clinical study in MDD patients, anticipated to start in early 2025

Indoco Remedies receives final ANDA approval from the USFDA for Cetirizine Hydrochloride Tablets

Cetirizine is used for relief of symptoms of hay fever and other allergic conditions

Clariant to launch eight new high-performing excipients at the CPHI Milan 2024

Clariant is launching high-performing pharmaceutical ingredients to support the evolution of safe and effective medicines

Dr. Reddy’s signs licensing agreement with Gilead Sciences to manufacture and commercialise Lenacapavir

Gilead Sciences first launched Lenacapavir under the brand name Sunlenca in the United States and Europe markets in the year 2022

Piramal Pharma Solutions announces US$ 80 million expansion plan for Sterile Injectables facility in Kentucky

Briefs: Lupin, Alembic Pharmaceuticals and Piramal Pharma

Lupin's Pithampur Unit-1 gets Form 483 from USFDA with 3 observations

Amcor's long-term SBTi targets confirmed

The net-zero target approval complements the company's near-term emission reduction targets

FDA approves Bristol Myers Squibb’s Cobenfy

A first-in-class muscarinic agonist for the treatment of schizophrenia in adults